Skip to main content

Table 3 Cardiovascular magnetic resonance and tissue characterisation parameters

From: Evolution of myocardial oedema and fibrosis in HIV infected persons after the initiation of antiretroviral therapy: a prospective cardiovascular magnetic resonance study

Parameter

Control group

HIV infected

p valuea

HIV infected 9 months on ART

p valueb

 

ART naïve

(n = 22)

(n = 73)

(n = 73)

(Controls)

(Naïve)

(ART)

LV mass indexed to height (g/m)

60 (51 to 71)

63 (53 to 73)

0.05#

63 (53 to 75)

0.8

LV end diastolic volume indexed to height (ml/m)

81 ± 13

86 ± 16

0.03##

89 ± 15

0.007

LV sphericity Index

0.53 ± 0.04

0.53 ± 0.05

0.6

0.52 ± 0.04

0.4

LV ejection fraction (%)

63 ± 5

60 ± 6

0.03

59 ± 5

0.6

Presence of pericardial effusion

4 (18%)

49 (67%)

< 0.001

46 (63%)

0.6

Abnormal T2 SIR region of interest

2.0 ± 0.2

2.0 ± 0.2

1.0

2.1 ± 0.4

0.05

Basal T2 SIR

1.5 ± 0.3

1.5 ± 0.2

0.7

1.6 ± 0.2

0.08

Midventricular T2 SIR

1.5 ± 0.2

1.5 ± 0.2

0.9

1.5 ± 0.2

0.5

Apical T2 SIR

1.4 ± 0.2

1.5 ± 0.2

0.3

1.5 ± 0.2

0.9

Global T2 SIR

1.5 ± 0.2

1.5 ± 0.2

0.5

1.5 ± 0.2

0.4

Basal native T1 mapping (ms)

1004 ± 24

1027 ± 38

0.01

1008 ± 32

< 0.001

Midventricular native T1 mapping (ms)

1003 ± 31

1025 ± 42

0.02

1011 ± 34

0.008

Apical native T1 mapping (ms)

1016 ± 43

1044 ± 61

0.05

1024 ± 42

0.001

Global native T1 mapping (ms)

1008 ± 31

1032 ± 44

0.02

1014 ± 34

< 0.001

Basal T2 mapping (ms)

45 ± 2

47 ± 3

0.002

47 ± 2

0.2

Midventricular T2 mapping (ms)

46 ± 2

48 ± 3

< 0.001

48 ± 2

0.4

Apical T2 mapping (ms)

48 ± 2

49 ± 3

0.07

50 ± 2

0.7

Global T2 mapping (ms)

4.6 ± 2

48 ± 3

0.006

48 ± 2

0.5

Basal EGE SIR

3.0 (2.3 to 3.6)*

3.0 (2.6 to 4.5) **

0.2

3.2 (2.6 to 4.1)***

0.9

Midventricular EGE SIR

2.6 (2.2 to 4.1)*

3.0 (2.5 to 4.0)**

0.4

3.0 (2.5 to 4.0)***

1.0

Apical EGE SIR

2.8 (2.2 to 3.8)*

2.9 (2.5 to 3.9)**

0.7

2.9 (2.4 to 4.1)***

0.9

Global EGE SIR

2.7 (2.3 to 3.9)*

2.9 (2.5 to 4.2)**

0.3

3.1 (2.5 to 4.0)***

0.8

Basal ECV (%)

23 ± 2*

25 ± 4

0.1

24 ± 3

0.003

Midventricular ECV (%)

24 ± 3*

25 ± 4

0.2

25 ± 3

0.03

Apical ECV (%)

25 ± 4*

28 ± 5

0.09

26 ± 3

< 0.001

Global ECV (%)

24 ± 38*

26 ± 4

0.1

25 ± 3

0.001

LGE present

1 (10%)*

35 (49%)

0.02

40 (55%)

0.2

Pattern of LGE

 Subepicardial

–

18 (50%)

–

18 (45%)

0.7

 Midmyocardial

1 (100%)*

12 (33%)

 

17 (43%)

 

Mixed

–

6 (17%)

 

5 (12%)

 

Segments with LGE

Basal infero-posterior

–

33 (49%)

–

35 (53%)

0.7

Mid infero-posterior

1 (100%)*

13 (19%)

 

10 (15%)

 

Basal septum

–

5 (7%)

 

8 (12%)

Mid septum

–

2 (3%)

 

2 (3%)

 

Basal antero-lateral

–

8 (12%)

 

6 (9%)

 

Mid antero-lateral

–

2 (3%)

 

2 (3%)

Apical segments

–

4 (6%)

 

3 (5%)

  1. Bold values indicate p value of ≤ 0.05
  2. Continuous variables are mean ± standard deviation or median (interquartile range) unless otherwise specified
  3. ECV extracellular volume fraction, EGE early gadolinium enhancement, LGE late gadolinium enhancement, LV left ventricle/left ventricular, SIR signal intensity ratio, STIR short tau inversion recovery
  4. *50% of the controls received gadolinium contrast (n = 11)
  5. **Three outliers were excluded from analysis
  6. ***One outlier was excluded from analysis
  7. #Mean difference = 6 g when corrected for age, sex, race, estimated glomerular filtration rate, and current tuberculous disease
  8. ##Mean difference = 6 ml when corrected for age, sex, race, ethanol use, and current tuberculous disease
Back to article page

Journal of Cardiovascular Magnetic Resonance

ISSN: 1532-429X

Contact us